New Molecule could Effectively Treat Chemotherapy-Induced Neuropathy

New Molecule could Effectively Treat Chemotherapy Induced Neuropathy

The molecule has a novel mode of action and it could be first treatment against this neurological complication, which does not have effective treatment currently.

Peripheral neuropathy is major disadvantage of certain chemotherapeutics used in the treatment of cancers. It is characterized by tingling, numbness, pain or alterations in the functionality of patients. Cancer patients have to go through this complication despite having a demonstrated negative impact on the quality of life, increasing care expenses, and preventing the complete and effective administration of the cytostatic treatment with the potential decrease of survival chances.

Researchers from Neuro-Oncology Unit of Bellvitge University Hospital – Catalan Institute of Oncology have reported that new molecule is capable of preventing progression of peripheral neuropathy induced by chemotherapy in cancer patients. It can significantly help in reducing symptoms of neuropathy in colon cancer.  Researchers at the HUB-ICO-IDIBELL Unit detected a new molecule developed by the Catalan laboratory Esteve as a candidate to prevent this adverse effect. “Through a public-private partnership, we have been able to design a Phase 2b clinical trial, which has allowed us to get a great deal of scientific information – effect on pain, pathophysiology – and draw conclusions as to the potential of the drug in the prevention of neuropathies during cytostatic treatment”, said explains Dr. Bruna, lead of the study.

According to Targeted Cancer Therapies Market report published by Coherent Market Insights, chemotherapy has adverse effects on cancer patients, which include neuropathy. In any case, improving pain control and reducing the occurrence of severe neuropathy is undoubtedly the most prominent benefit of the development of this novel drug. As a result of the study, it was observed that cancer patients who took new drug showed low symptoms of disorders regarding nerve dysfunction. “Given the usual pace of clinical trials and drug agencies following fast-track approval processes in severe or orphan pathologies, this new drug could potentially reach the market soon, since it would be the first available treatment to avoid this type of neuropathy. In addition, it has other medical uses as a non-opioid analgesic”, said Bruna.

The molecule has a novel mode of action and it could be first treatment against this neurological complication, which does not have effective treatment currently.
Peripheral neuropathy is major disadvantage of certain chemotherapeutics used in the treatment of cancers. It is characterized by tingling, numbness, pain or alterations in the functionality of patients. Cancer patients have to go through this complication despite having a demonstrated negative impact on the quality of life, increasing care expenses, and preventing the complete and effective administration of the cytostatic treatment with the potential decrease of survival chances.
Researchers from Neuro-Oncology Unit of Bellvitge University Hospital – Catalan Institute of Oncology have reported that new molecule is capable of preventing progression of peripheral neuropathy induced by chemotherapy in cancer patients. It can significantly help in reducing symptoms of neuropathy in colon cancer. Researchers at the HUB-ICO-IDIBELL Unit detected a new molecule developed by the Catalan laboratory Esteve as a candidate to prevent this adverse effect. “Through a public-private partnership, we have been able to design a Phase 2b clinical trial, which has allowed us to get a great deal of scientific information – effect on pain, pathophysiology – and draw conclusions as to the potential of the drug in the prevention of neuropathies during cytostatic treatment”, said explains Dr. Bruna, lead of the study.
According to Targeted Cancer Therapies Market report published by Coherent Market Insights, chemotherapy has adverse effects on cancer patients, which include neuropathy. In any case, improving pain control and reducing the occurrence of severe neuropathy is undoubtedly the most prominent benefit of the development of this novel drug. As a result of the study, it was observed that cancer patients who took new drug showed low symptoms of disorders regarding nerve dysfunction. “Given the usual pace of clinical trials and drug agencies following fast-track approval processes in severe or orphan pathologies, this new drug could potentially reach the market soon, since it would be the first available treatment to avoid this type of neuropathy. In addition, it has other medical uses as a non-opioid analgesic”, said Bruna.

You may be interested

Smart Nanotechnology Enlivens Wooden Ships and Artifacts
Business
Business

Smart Nanotechnology Enlivens Wooden Ships and Artifacts

Mohit Joshi - January 28, 2019

Scientists developed an innovative approach using ‘smart’ nanocomposites to conserve 16th-century British warship, the Mary Rose, and its artifacts. Shipwrecks are preserved in sediments under cold water,…

Researchers Discovered New Properties of Ferroelectric Crystal
Business
Business

Researchers Discovered New Properties of Ferroelectric Crystal

Mohit Joshi - January 25, 2019

Researchers discovered new properties of ferroelectric crystal, according to a study published on July 10, 2018. This study was conducted by a team of researchers from China.…

Researchers Develop Novel Antibody to Knockdown of Protein in Vertebrates
Healthcare
Healthcare

Researchers Develop Novel Antibody to Knockdown of Protein in Vertebrates

Mohit Joshi - January 24, 2019

Researchers from Technische Universität Dresden developed a synthetic antibody that improves functional analysis of proteins. A research led by Dr. Jörg Mansfeld of the Biotechnology Center of…

Most from this category